Luye Pharma Group Balance Sheet Health
Financial Health criteria checks 4/6
Luye Pharma Group has a total shareholder equity of CN¥14.1B and total debt of CN¥9.4B, which brings its debt-to-equity ratio to 66.6%. Its total assets and total liabilities are CN¥27.2B and CN¥13.1B respectively. Luye Pharma Group's EBIT is CN¥1.3B making its interest coverage ratio 2.9. It has cash and short-term investments of CN¥6.5B.
Key information
66.6%
Debt to equity ratio
CN¥9.39b
Debt
| Interest coverage ratio | 2.9x |
| Cash | CN¥6.48b |
| Equity | CN¥14.08b |
| Total liabilities | CN¥13.11b |
| Total assets | CN¥27.20b |
Recent financial health updates
Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?
Aug 29
Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden
Apr 26Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt
Dec 19Is Luye Pharma Group (HKG:2186) A Risky Investment?
Sep 12Is Luye Pharma Group (HKG:2186) Using Too Much Debt?
May 10We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt
Sep 20Recent updates
Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares
Sep 25Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?
Aug 29Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors
Jun 19We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed
May 21Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden
Apr 26Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?
Feb 29Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S
Jan 09Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt
Dec 19A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)
Nov 24Is Luye Pharma Group (HKG:2186) A Risky Investment?
Sep 12Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price
Aug 17Is Luye Pharma Group (HKG:2186) Using Too Much Debt?
May 10We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt
Sep 20Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook
Apr 06Luye Pharma Group's (HKG:2186) Shareholders Are Down 31% On Their Shares
Mar 17Financial Position Analysis
Short Term Liabilities: 2186's short term assets (CN¥12.5B) exceed its short term liabilities (CN¥9.8B).
Long Term Liabilities: 2186's short term assets (CN¥12.5B) exceed its long term liabilities (CN¥3.3B).
Debt to Equity History and Analysis
Debt Level: 2186's net debt to equity ratio (20.6%) is considered satisfactory.
Reducing Debt: 2186's debt to equity ratio has reduced from 70.7% to 66.6% over the past 5 years.
Debt Coverage: 2186's debt is not well covered by operating cash flow (5.4%).
Interest Coverage: 2186's interest payments on its debt are not well covered by EBIT (2.9x coverage).